The P-II clinical trial evaluates the safety & immunogenicity GBP410 vs control vaccine in infants (n=140, aged 12-15mos. & n=712, aged 42-89days) across the US, Canada & Honduras
The results depicted comparable immunogenicity of GBP410 vs control vaccine following primary vaccination at 2, 4, & 6mos. of age along with the booster vaccination at 12-15mos. Additionally, GBP410 showed a well-tolerated safety profile& did not interfere with the immunogenicity & safety profile of the co-administered recommended pediatric vaccines like tetanus, polio etc.
A joint development of SK Bioscience & Sanofi, GBP410 is a pneumococcal conjugate vaccine that combines specific proteins with the polysaccharide capsule of Streptococcus pneumoniae which causes pneumococcal diseases like pneumonia & invasive pneumococcal disease
Ref: PR Newswire | Image: Sanofi
Related News:- GSK and SK Bioscience Initiate P-III Study of GBP510 Against AZ/Oxford’s COVID-19 Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
